Lorrain Daniel S. 4

4 · Contineum Therapeutics, Inc. · Filed Feb 26, 2026

AI-generated summary of this filing

Updated Feb 26, 2026

Contineum (CTNM) CSO Daniel S. Lorrain Exercises Options, Sells Shares

What Happened

Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), exercised stock options and immediately sold the resulting shares. On Feb 24, 2026 he exercised 4,300 options at $1.01/share (cost $4,343) and sold those 4,300 shares for a weighted average $16.03/share (proceeds $68,936). On Feb 25, 2026 he exercised 3,824 options at $1.01/share (cost $3,862) and sold those 3,824 shares for a weighted average $16.01/share (proceeds $61,228). Total proceeds from the sales were $130,164; total exercise cost was $8,205, for net proceeds of about $121,959. The filing also reports the related derivative instruments were disposed at $0.00 (i.e., the options were converted/exercised).

Key Details

Transaction dates: Feb 24–25, 2026; Form 4 filed Feb 26, 2026 (timely filing).
Exercise price: $1.01 per share for both exercises; options are fully vested (F4).
Sales: 4,300 shares sold at a weighted avg $16.03 (range $16.00–$16.15 per F2) and 3,824 shares sold at a weighted avg $16.01 (range $16.00–$16.05 per F3).
Total shares involved: 8,124 shares sold; total gross proceeds ≈ $130,164; net after exercise ≈ $121,959.
Plan/condition: Transactions were executed under a 10b5-1 trading plan adopted Sept 23, 2025 (F1).
Shares owned after transaction: Not disclosed in the supplied Form 4 details.

Context

This was an option exercise followed by same-day sales (a cashless-style transaction): M = option exercise/conversion, S = open-market sale. The reported $0.00 disposals reflect removal of the derivative (the options) upon exercise.
Sales executed under a 10b5-1 plan are typically pre-arranged and routine; the filing is factual and does not indicate insider motivation.

Form 4

Period: 2026-02-24

Chief Scientific Officer

Transactions

Exercise/Conversion
Class A Common Stock
[F1]
2026-02-24$1.01/sh+4,300$4,343→ 160,352 total
Sale
Class A Common Stock
[F1][F2]
2026-02-24$16.03/sh−4,300$68,936→ 156,052 total
Exercise/Conversion
Class A Common Stock
[F1]
2026-02-25$1.01/sh+3,824$3,862→ 159,876 total
Sale
Class A Common Stock
[F1][F3]
2026-02-25$16.01/sh−3,824$61,228→ 156,052 total
Exercise/Conversion
Stock Option (right to buy)
[F1][F4]
2026-02-24−4,300→ 71,130 total
Exercise: $1.01Exp: 2030-02-24→ Class A Common Stock (4,300 underlying)
Exercise/Conversion
Stock Option (right to buy)
[F1][F4]
2026-02-25−3,824→ 67,306 total
Exercise: $1.01Exp: 2030-02-24→ Class A Common Stock (3,824 underlying)

Holdings

Footnotes (4)

[F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
[F4]The stock options are fully vested and exercisable.

Signature

/s/ Peter Slover, Attorney-in-Fact|2026-02-26

1 file